Hormonaly

Clinical pocket reference · for licensed clinicians

The Peptide Pocket Guide

House-graded evidence, dated regulatory status and a dosing reference that identifies the provenance of each dose, for the peptides your patients ask about.

Second edition · October 2026



Fady Hannah-Shmouni, MD FRCPC
Faculty and medical reviewer

Hormonaly ACADEMY | built on Perceptors AI

Hormonaly ACADEMY

The Peptide Pocket Guide

Second edition · October 2026

A clinical pocket reference for physicians, nurse practitioners and physician associates, nurses and pharmacists.

137 entries in 14 parts. Every entry carries a house evidence grade, A to D (adapted from GRADE; see How strong is the evidence?), for the use named beside it, the regulator and month behind every status line, and label doses for approved drugs. Each entry's dose block identifies the provenance of each dose (label, trial, nomination, topical use level, reported practice, or none), and a separate dosing chapter tabulates documented label, trial and nomination exposures. Status is as of 30 October 2026.

Author

Fady Hannah-Shmouni, MD FRCPC

Endocrinologist and biochemical geneticist

Faculty and medical reviewer, Hormonaly Academy

Educational content for licensed clinicians. It does not replace clinical judgment, specialist input or formal guidelines.

Second edition, October 2026. First published August 2026. Evidence cutoff and regulatory status date: 30 October 2026; sources verified through 7 November 2026. Medical review completed 1 November 2026.

The Peptide Pocket Guide

Contents

Quick access: urgent actions and clinical topics 6
How to use this guide 8
How strong is the evidence? 11
What the references mean 14
Editorial standards and evidence philosophy 15
Peptide fundamentals 17
A short history of peptide medicines 24

PART 01 Metabolic & Incretin 27
- CagriSema (cagrilintide/semaglutide) A 28
- Dasiglucagon A 30
- Enlicitide A 32
- Exenatide A 34
- Glucagon A 37
- Insulin A 39
- Liraglutide A 42
- Lixisenatide A 44
- Mazdutide A 46
- Retatrutide A 48
- Semaglutide A 51
- Survodutide A 55
- Tirzepatide A 57
- Cagrilintide B 60
- Petrelintide B 62
- Pramlintide B 64
- Amycretin (zenagamtide) C 66
- Pemvidutide C 68

PART 02 Growth-Hormone Axis 70
- Tesamorelin A 71
- AOD-9604 C 73
- CJC-1295 C 76
- GHRP-2 C 78
- Ipamorelin C 80
- Sermorelin C 82
- Fragment 176-191 (hGH 176-191) D 84
- GHRP-6 D 86
- Hexarelin D 88
- Mechano growth factor (MGF / PEG-MGF) D 90

PART 03 Regenerative & Repair 93
- Thymosin α1 B 94

ARA-290	C	96
Glutathione (IV, oral and topical)	C	98
Thymosin beta-4 (full-length)	C	101
BPC-157	D	105
KPV	D	109
TB-500 (Ac-LKKTETQ)	D	112
Thymulin	D	115
PART 04 Dermatology & Cosmetic		**117**
Argireline	C	118
GHK-Cu	C	120
Hexapeptide-9	D	122
Palmitoyl pentapeptide-4 (Matrixyl)	C	124
Tripeptide-10 citrulline	C	126
Acetyl octapeptide-3 (SNAP-8)	D	128
Acetyl tetrapeptide-5	D	130
Carnosine	D	132
Dipeptide diaminobutyroyl benzylamide diacetate (Syn-Ake)	D	134
GHK	D	136
Leuphasyl	D	138
Matrixyl 3000	D	140
Nonapeptide-1	D	142
Palmitoyl hexapeptide-12	D	144
Palmitoyl tetrapeptide-7	D	146
Palmitoyl Tripeptide-1	D	148
Palmitoyl tripeptide-38	D	150
PTD-DBM	D	152
Zinc Thymulin	D	154
PART 05 Bone & Mineral Metabolism		**156**
Abaloparatide	A	157
Etelcalcetide	A	159
Teriparatide	A	161
Calcitonin (salmon)	B	163
Palopegteriparatide	B	165
Vosoritide	B	167
PART 06 Somatostatin Analogues		**169**
Lanreotide	A	170
Octreotide	A	172
Pasireotide	B	175
PART 07 Melanocortin & Sexual		**177**
Bremelanotide	A	178
Afamelanotide	B	180
Setmelanotide	B	182
Melanotan II	C	185
PT-141	C	188

PART 08 Reproductive & Pituitary 190
Cetrorelix A 191
Degarelix A 193
Desmopressin A 195
Ganirelix A 198
Goserelin A 200
Leuprolide A 202
Oxytocin A 205
Triptorelin A 207
Corticotropin (repository ACTH) B 209
Cosyntropin (tetracosactide) B 211
Histrelin B 213
Nafarelin B 215
Kisspeptin-10 C 217
Gonadorelin D 219

PART 09 Mitochondrial & Longevity 222
SS-31 (Elamipretide) C 223
FOXO4-DRI D 225
G-Klotho Frag 33 D 227
Humanin D 229
MOTS-c D 231

PART 10 Peptide Bioregulators 234
Peptide bioregulators: what the category claims 235
Cortexin C 240
Retinalamin C 243
Thymalin C 246
Thymogen C 249
Pineamin C 252
Prostatilen (bovine prostate extract) C 254
Bronchogen D 257
Cardiogen D 259
Chonluten D 262
Cortagen D 264
Crystagen D 266
Epitalon D 269
Livagen D 272
Ovagen D 274
Pancragen D 276
Pinealon D 279
Prostamax D 281
Testagen D 283
Vesugen D 285
Vilon D 288

PART 11 Neurological 290

Aviptadil (vasoactive intestinal peptide)	B	291
Trofinetide	B	294
Cerebrolysin	C	297
DSIP (emideltide)	C	300
Selank	C	303
Semax	C	305
GB-115 (Ranquilon)	C	308
Noopept (omberacetam)	C	311
Dihexa	D	314
PE-22-28	D	316
PART 12 Investigational Oncology		**318**
Met-5-Enkephalin	D	319
PNC-27	D	321
PART 13 GI & Intestinal		**323**
Linaclotide	A	324
Plecanatide	A	326
Teduglutide	A	328
Apraglutide	B	330
Glepaglutide	B	332
Secretin (human, synthetic)	B	334
Larazotide acetate	C	336
Dalargin	C	338
PART 14 Immunology, Allergy & Hematology		**341**
Difelikefalin	A	342
Icatibant	A	344
Pegcetacoplan	A	346
Rusfertide	A	350
Zilucoplan	A	353
Imunofan	C	355
Tactivin (T-activin)	C	357
LL-37 (Cathelicidin)	C	360
PEPITEM	D	362
Non-peptide and protein comparators		**364**
Selected peptide dose and exposure reference		**378**
Clinical pearls		**405**
Consent and documentation		**409**
Growth-hormone excess: symptoms and bloodwork		**411**
Hypersensitivity and anaphylaxis with peptides		**419**
Deaths, ICU admissions and emergency visits: the documented record		**428**
Skin manifestations of peptide use		**443**
Adverse effects and overdose		**451**
Lab and monitoring reference		**455**
Receptor desensitization		**461**

Peptide stacking and the single-ingredient rule 463
Neuropsychiatric signals in GLP-1 therapy 469
Controlled human trials of Russian and Soviet peptide preparations 472
Russian and Soviet preparations in the molekul.io library: where each is covered 478
Anti-doping testing 488
US regulatory status at a glance — October 2026 490
The HHS enforcement-discretion policy (October 2026) 502
The 503A bulks list, categories and the July 2026 committee 513
What the committee saw: reported evidence, July 2026 PCAC 519
US compounding law for prescribers 530
Cosmetic, compounded, or supplement? 537
Jurisdictional snapshot — October 2026 541
Case study: Lilly v. FDA 546
Index of names and aliases 550
About the author 560
About this guide 562

Before you start

Quick access: urgent actions and clinical topics

Where to turn first. Page numbers lead to the start of each chapter; the detailed protocol and its sources are there.

URGENT ACTIONS

SITUATION	GO TO	PAGE
Suspected anaphylaxis after an injection	Hypersensitivity and anaphylaxis with peptides: Immediate management, including the life-threatening or refractory branch	419
Hypoglycemia or overdose with an unknown injectable	Adverse effects and overdose	451
Headache, visual change, swelling or high glucose on GH-axis peptides	Growth-hormone excess: symptoms and bloodwork	411
Injection-site nodules or abscess that fail antibiotics	Skin manifestations of peptide use	443
Suicidal thoughts or mood change on a GLP-1 drug	Neuropsychiatric signals in GLP-1 therapy	469
Death, ICU admission or emergency visit: what is documented and how to report	Deaths, ICU admissions and emergency visits: the documented record	428

This page points to the protocols; it does not replace them. Treat suspected anaphylaxis first and read later.

CLINICAL TOPICS

TOPIC	GO TO	PAGE
Which dose numbers have a documented source or provenance	Selected peptide dose and exposure reference	378
No established dose-response: longevity, Alzheimer, Parkinson, alcohol use, BPC-157	Selected peptide dose and exposure reference	378
Somatropin (HGH) exposure by dose band in IU	Selected peptide dose and exposure reference	378
Hair loss on GLP-1 drugs	Skin manifestations of peptide use	443

TOPIC	GO TO	PAGE
New moles or pigment change on melanotan	Skin manifestations of peptide use	443
Labs to order and monitoring schedules	Lab and monitoring reference	455
Mixing peptides in one vial	Peptide stacking and the single-ingredient rule	463
Tolerance, cycling and off-periods	Receptor desensitization	461
Reconstitution, storage and certificates of analysis	Peptide fundamentals	17
Athletes and drug testing	Anti-doping testing	488
The six HHS peptides and compounding conditions	The HHS enforcement-discretion policy (October 2026)	502
Can a pharmacy compound it: 503A and 503B	US compounding law for prescribers	530
FDA status of a named peptide	US regulatory status at a glance — October 2026	490
State boards and other countries	Jurisdictional snapshot — October 2026	541
Cosmetic, compounded or supplement labeling	Cosmetic, compounded, or supplement?	537
Russian and Soviet products and their trials	Controlled human trials of Russian and Soviet peptide preparations	472
Non-peptides patients ask about (NAD+, methylene blue, bromantane)	Non-peptide and protein comparators	364
What the evidence grades mean	How strong is the evidence?	11
Consent for unapproved use	Consent and documentation	409
Short clinical answers	Clinical pearls	405

Before you start

How to use this guide

What each entry contains, how the book is ordered, and what the shaded box on every page is for.

This second edition has 137 entries in 14 parts. An entry is a reader route, not a count of distinct molecules. Most entries are single peptides of 2 to 50 amino acids, with insulin (51 residues) as the stated boundary case. Others are peptide analogues and conjugates whose active part is a peptide (fatty-acid acylated incretins, the copper complex GHK-Cu, the pegylated peptides pegcetacoplan and palopegteriparatide), fixed combinations (CagriSema) and cosmetic blends (Matrixyl 3000), and animal tissue extracts of undefined composition (Cortexin, Retinalamin, Thymalin, Cerebrolysin). A few are marketed products whose identity rests on the seller's description. Bremelanotide and PT-141 are the same molecule under two names. The bremelanotide entry covers the approved subcutaneous product; the PT-141 entry covers the intranasal and compounded forms and their separate trials, so the two grades rate different uses and products, not different molecules. Small molecules and proteins that patients group with peptides, such as orforglipron, MK-677, creatine, somatropin and hCG, are graded in one comparator chapter at the back. Approved drugs sit beside investigational, compounded and research-only agents, because patients arrive taking all of them.

Every entry follows one template, so the same field sits in the same place on every page.

READING AN ENTRY

Evidence grade	A to D, on a house evidence scale adapted from GRADE. It rates the clinical evidence for the use named under it, not legality or popularity. An approved drug can carry a low grade for a use it is marketed for. See How strong is the evidence?
Hedge chip	Appears beside a D. Mechanism only, Cell data, Ex vivo human tissue, Mouse data, Rodent data or Animal data mark non-human evidence; Limited human data marks small human reports at high risk of bias.
Class label	The pharmacologic class.
Sequence and size	One-letter sequence or a structural description, never truncated.
Indications	Approved indications first, then investigational uses, off-label uses of approved drugs, and unapproved uses of unapproved substances, each marked as such.